| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 170,992 | 150,042 | 121,463 | 104,762 |
| Cost of revenue (excluding amortization and depreciation) | 11,912 | 13,448 | 9,789 | 8,437 |
| Research and development | 40,162 | 49,541 | 44,785 | 45,388 |
| Selling, general and administrative | 150,235 | 130,280 | 120,787 | 95,564 |
| Loss in fair value of contingent consideration | 13,185 | -8,102 | 1,512 | 16,391 |
| Intangible asset amortization | 1,607 | 1,589 | 1,572 | 1,606 |
| Total operating expenses | 217,101 | 186,756 | 178,445 | 167,386 |
| Loss from operations | -46,109 | -36,714 | -56,982 | -62,624 |
| Interest expense, net | -1,120 | -1,834 | -2,431 | -1,978 |
| Loss on debt extinguishment | - | -10,385 | - | - |
| Loss before income taxes | -47,229 | -48,933 | -59,413 | -64,602 |
| Income tax benefit | - | -960 | - | - |
| Income tax benefit | - | -1,000 | - | - |
| Net loss | -47,229 | -47,973 | -59,413 | -64,602 |
| Net loss per common share, basic | -0.94 | -0.97 | -1.22 | -1.34 |
| Net loss per common share, diluted | -0.94 | -0.97 | -1.22 | -1.34 |
| Weighted average common shares outstanding, basic | 50,021,851 | 49,442,001 | 48,871,163 | 48,140,519 |
| Weighted average common shares outstanding, diluted | 50,021,851 | 49,442,001 | 48,871,163 | 48,140,519 |
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM)